Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Size and Forecast (2021 - 2031)
The Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) market is poised for significant growth, with projections indicating it will reach approximately US$ 8,140.2 million by 2031, up from US$ 1,553.8 million in 2024. This growth trajectory reflects a remarkable compound annual growth rate (CAGR) of 26.9% from 2025 to 2031.
Executive Summary and Market Analysis
The market is categorized into several key regions, including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The expansion of this market is primarily fueled by a combination of robust infrastructure, supportive government policies, and an increasing number of CDMOs in the region. Countries such as China, Japan, and Singapore are making substantial investments in biotechnology, fostering an environment conducive to the development of cell and gene therapies. Furthermore, governments in these regions have implemented favorable regulatory frameworks aimed at expediting the approval processes for cell and gene therapies, which in turn encourages early-stage clinical trials and conditional approvals.
Strategic partnerships and a growing demand for advanced therapeutic solutions are also driving the market. The relatively lower costs associated with clinical trials and manufacturing in the Asia-Pacific region, coupled with access to large patient populations, make it an attractive destination for global biopharmaceutical companies seeking CDMO partners. The increasing presence of multinational pharmaceutical firms and their collaborations with regional CDMOs have led to rapid infrastructure development, including the establishment of state-of-the-art Good Manufacturing Practice (GMP) facilities. Local CDMOs are also enhancing their capabilities to support the intricate production processes associated with cell and gene therapies, such as viral vector manufacturing, cell processing, and cryopreservation logistics.
Strategic Insights
Market Segmentation Analysis
The Asia Pacific CDMO market for cell and gene therapy is segmented by service type, product type, and end user.
The increasing demand for cell and gene therapies is driving biopharmaceutical companies to seek out CDMOs that can provide advanced facilities and technologies necessary for scaling up production while ensuring compliance with quality and regulatory standards. The production of complex and personalized therapies necessitates specialized infrastructure capable of maintaining high manufacturing standards. This includes the production of viral vectors used in gene therapies, which requires GMP-compliant facilities to ensure the safety, consistency, and quality of the final products. These facilities must be equipped to handle complex biological materials, including live cells and genetically modified organisms, in controlled environments.
The adoption of automated cell culture systems, continuous manufacturing processes, and digital quality monitoring systems is enhancing the efficiency and growth of gene therapy production. The demand for specialized facilities presents a significant opportunity for CDMOs, as it is often more cost-effective for biopharmaceutical companies to collaborate with CDMOs that possess the necessary technology and infrastructure. For example, in 2023, Bristol-Myers Squibb partnered with a CDMO for the production of its CAR-T cell therapy, Breyanzi, which involves harvesting, modifying, and expanding a patient’s T-cells—a process that requires specialized technology and facilities to achieve the desired therapeutic outcomes. By leveraging the expertise of CDMOs, Bristol-Myers Squibb was able to scale production while ensuring compliance with regulatory standards and maintaining product quality.
Country Insights
The Asia Pacific CDMO market is further segmented by country, with China, Japan, India, Australia, South Korea, and the Rest of APAC being the primary regions. China is expected to hold the largest market share in 2024.
China is rapidly establishing itself as a global leader in cell and gene therapy manufacturing, supported by its robust infrastructure, favorable policies, and a growing number of CDMOs. Notable domestic CDMOs, such as WuXi Biologics and GenScript Biotech, are at the forefront of this growth, having developed comprehensive platforms for cell and gene therapy. WuXi Biologics, for instance, operates over 18 manufacturing sites worldwide, including several in China, and offers extensive services across the cell and gene therapy value chain. In 2021, the company launched its MFG5 facility in Wuxi, featuring a 60,000-liter single-use bioreactor capacity, highlighting China's capabilities in large-scale production.
GenScript Biotech has also made significant advancements in the sector, launching its CDMO segment, ProBio, and inaugurating China’s largest commercial GMP plasmid manufacturing facility in December 2024. This facility, located in Zhenjiang, Jiangsu Province, spans 6,400 m? and provides comprehensive services from preclinical studies to commercial-scale production, supporting the rapid development of mRNA and viral vector-based therapies.
Company Profiles
Key players in the Asia Pacific CDMO market include Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Pluri Inc, Aenova Holding GmbH, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, Thermo Fisher Scientific Inc., Minaris Advanced Therapies, and SK pharmteco Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to their clients.
Executive Summary and Market Analysis
The market is categorized into several key regions, including China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The expansion of this market is primarily fueled by a combination of robust infrastructure, supportive government policies, and an increasing number of CDMOs in the region. Countries such as China, Japan, and Singapore are making substantial investments in biotechnology, fostering an environment conducive to the development of cell and gene therapies. Furthermore, governments in these regions have implemented favorable regulatory frameworks aimed at expediting the approval processes for cell and gene therapies, which in turn encourages early-stage clinical trials and conditional approvals.
Strategic partnerships and a growing demand for advanced therapeutic solutions are also driving the market. The relatively lower costs associated with clinical trials and manufacturing in the Asia-Pacific region, coupled with access to large patient populations, make it an attractive destination for global biopharmaceutical companies seeking CDMO partners. The increasing presence of multinational pharmaceutical firms and their collaborations with regional CDMOs have led to rapid infrastructure development, including the establishment of state-of-the-art Good Manufacturing Practice (GMP) facilities. Local CDMOs are also enhancing their capabilities to support the intricate production processes associated with cell and gene therapies, such as viral vector manufacturing, cell processing, and cryopreservation logistics.
Strategic Insights
Market Segmentation Analysis
The Asia Pacific CDMO market for cell and gene therapy is segmented by service type, product type, and end user.
- By Service Type: The market is divided into Drug Development and Manufacturing, Testing and Regulatory Services, and Others. In 2024, Drug Development and Manufacturing is expected to hold the largest market share.
- By Product Type: The market is categorized into Gene Therapy and Cell Therapy, with Gene Therapy anticipated to dominate the market share in 2024.
- By End User: The market is segmented into Pharmaceutical Companies, Biopharmaceutical Companies, and Others, where Biopharmaceutical Companies are projected to hold the largest share in 2024.
The increasing demand for cell and gene therapies is driving biopharmaceutical companies to seek out CDMOs that can provide advanced facilities and technologies necessary for scaling up production while ensuring compliance with quality and regulatory standards. The production of complex and personalized therapies necessitates specialized infrastructure capable of maintaining high manufacturing standards. This includes the production of viral vectors used in gene therapies, which requires GMP-compliant facilities to ensure the safety, consistency, and quality of the final products. These facilities must be equipped to handle complex biological materials, including live cells and genetically modified organisms, in controlled environments.
The adoption of automated cell culture systems, continuous manufacturing processes, and digital quality monitoring systems is enhancing the efficiency and growth of gene therapy production. The demand for specialized facilities presents a significant opportunity for CDMOs, as it is often more cost-effective for biopharmaceutical companies to collaborate with CDMOs that possess the necessary technology and infrastructure. For example, in 2023, Bristol-Myers Squibb partnered with a CDMO for the production of its CAR-T cell therapy, Breyanzi, which involves harvesting, modifying, and expanding a patient’s T-cells—a process that requires specialized technology and facilities to achieve the desired therapeutic outcomes. By leveraging the expertise of CDMOs, Bristol-Myers Squibb was able to scale production while ensuring compliance with regulatory standards and maintaining product quality.
Country Insights
The Asia Pacific CDMO market is further segmented by country, with China, Japan, India, Australia, South Korea, and the Rest of APAC being the primary regions. China is expected to hold the largest market share in 2024.
China is rapidly establishing itself as a global leader in cell and gene therapy manufacturing, supported by its robust infrastructure, favorable policies, and a growing number of CDMOs. Notable domestic CDMOs, such as WuXi Biologics and GenScript Biotech, are at the forefront of this growth, having developed comprehensive platforms for cell and gene therapy. WuXi Biologics, for instance, operates over 18 manufacturing sites worldwide, including several in China, and offers extensive services across the cell and gene therapy value chain. In 2021, the company launched its MFG5 facility in Wuxi, featuring a 60,000-liter single-use bioreactor capacity, highlighting China's capabilities in large-scale production.
GenScript Biotech has also made significant advancements in the sector, launching its CDMO segment, ProBio, and inaugurating China’s largest commercial GMP plasmid manufacturing facility in December 2024. This facility, located in Zhenjiang, Jiangsu Province, spans 6,400 m? and provides comprehensive services from preclinical studies to commercial-scale production, supporting the rapid development of mRNA and viral vector-based therapies.
Company Profiles
Key players in the Asia Pacific CDMO market include Charles River Laboratories International Inc, Catalent Inc, Lonza Group AG, WuXi Biologics Inc, Pluri Inc, Aenova Holding GmbH, Takara Bio Inc, FUJIFILM Holdings Corp, AGC Biologics AS, Thermo Fisher Scientific Inc., Minaris Advanced Therapies, and SK pharmteco Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to their clients.
1. INTRODUCTION
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET LANDSCAPE
4.2 PEST Analysis
5. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2024 - 2031
6.2 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Forecast and Analysis
7. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET REVENUE ANALYSIS - BY SERVICE TYPE
7.1 Drug Development and Manufacturing
7.1.1 Overview
7.1.2 Drug Development and Manufacturing: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Testing and Regulatory Services
7.2.1 Overview
7.2.2 Testing and Regulatory Services: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Others
7.3.1 Overview
7.3.2 Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
8.1 Gene Therapy
8.1.1 Overview
8.1.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Therapy
8.2.1 Overview
8.2.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET REVENUE ANALYSIS - BY END USER
9.1 Pharmaceutical Companies
9.1.1 Overview
9.1.2 Pharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Biopharmaceutical Companies
9.2.1 Overview
9.2.2 Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET - COUNTRY ANALYSIS
10.1 Asia Pacific
10.1.1 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue and Forecast and Analysis - by Country
10.1.1.1 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue and Forecast and Analysis - by Country
10.1.2.2 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.1.2.2.2 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.1.2.2.3 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.2.3.3 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.2.3.3.2 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.2.3.3.3 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.3.4.4 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.3.4.4.2 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.3.4.4.3 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.4.5.5 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4.5.5.1 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.4.5.5.2 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.4.5.5.3 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.5.6.6 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5.6.6.1 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.5.6.6.2 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.5.6.6.3 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.6.7.7 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6.7.7.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.6.7.7.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.6.7.7.3 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
11 COMPETITIVE LANDSCAPE
11.1 Global Company Market Share Analysis, 2024
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Charles River Laboratories International Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Catalent Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Lonza Group AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 WuXi Biologics Inc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Pluri Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Aenova Holding GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takara Bio Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 FUJIFILM Holdings Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AGC Biologics AS
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Thermo Fisher Scientific Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Minaris Advanced Therapies
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 SK pharmteco Inc
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
1.1 Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
2.2 Market Attractiveness
3. RESEARCH METHODOLOGY
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET LANDSCAPE
4.2 PEST Analysis
5. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET - KEY MARKET DYNAMICS
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints:
6. CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET - ASIA PACIFIC MARKET ANALYSIS
6.1 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2024 - 2031
6.2 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Forecast and Analysis
7. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET REVENUE ANALYSIS - BY SERVICE TYPE
7.1 Drug Development and Manufacturing
7.1.1 Overview
7.1.2 Drug Development and Manufacturing: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.2 Testing and Regulatory Services
7.2.1 Overview
7.2.2 Testing and Regulatory Services: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
7.3 Others
7.3.1 Overview
7.3.2 Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET REVENUE ANALYSIS - BY PRODUCT TYPE
8.1 Gene Therapy
8.1.1 Overview
8.1.2 Gene Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
8.2 Cell Therapy
8.2.1 Overview
8.2.2 Cell Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET REVENUE ANALYSIS - BY END USER
9.1 Pharmaceutical Companies
9.1.1 Overview
9.1.2 Pharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.2 Biopharmaceutical Companies
9.2.1 Overview
9.2.2 Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10. ASIA PACIFIC CELL AND GENE THERAPY CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION MARKET - COUNTRY ANALYSIS
10.1 Asia Pacific
10.1.1 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue and Forecast and Analysis - by Country
10.1.1.1 Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue and Forecast and Analysis - by Country
10.1.2.2 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.1.2.2.1 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.1.2.2.2 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.1.2.2.3 China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.2.3.3 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.2.3.3.1 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.2.3.3.2 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.2.3.3.3 Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.3.4.4 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.3.4.4.1 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.3.4.4.2 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.3.4.4.3 India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.4.5.5 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.4.5.5.1 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.4.5.5.2 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.4.5.5.3 Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.5.6.6 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.5.6.6.1 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.5.6.6.2 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.5.6.6.3 South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
10.6.7.7 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
10.6.7.7.1 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Service Type
10.6.7.7.2 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by Product Type
10.6.7.7.3 Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share - by End User
11 COMPETITIVE LANDSCAPE
11.1 Global Company Market Share Analysis, 2024
12 INDUSTRY LANDSCAPE
12.1 Overview
12.2 New Product Development
12.3 Merger and Acquisition
12.4 Other Strategic Developments
13 COMPANY PROFILES
13.1 Charles River Laboratories International Inc
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Catalent Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Lonza Group AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 WuXi Biologics Inc
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Pluri Inc
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Aenova Holding GmbH
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Takara Bio Inc
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 FUJIFILM Holdings Corp
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 AGC Biologics AS
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Thermo Fisher Scientific Inc.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
13.11 Minaris Advanced Therapies
13.11.1 Key Facts
13.11.2 Business Description
13.11.3 Products and Services
13.11.4 Financial Overview
13.11.5 SWOT Analysis
13.11.6 Key Developments
13.12 SK pharmteco Inc
13.12.1 Key Facts
13.12.2 Business Description
13.12.3 Products and Services
13.12.4 Financial Overview
13.12.5 SWOT Analysis
13.12.6 Key Developments
14. APPENDIX
14.1 About The Insight Partners
LIST OF TABLES
Table 1. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation
Table 3. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 5. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 6. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 7. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 9. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 11. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 12. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 13. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 14. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 15. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 16. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 17. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 18. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 19. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 20. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 21. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 23. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 24. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 25. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 1. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation
Table 3. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Table 4. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 5. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 6. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 7. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Country
Table 8. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 9. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 10. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 11. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 12. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 13. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 14. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 15. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 16. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 17. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 18. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 19. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 20. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 21. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 22. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
Table 23. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Service Type
Table 24. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by Product Type
Table 25. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million) - by End User
LIST OF FIGURES
Figure 1. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2024 - 2031
Figure 6. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by Service Type, 2024 and 2031
Figure 7. Drug Development and Manufacturing: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 8. Testing and Regulatory Services: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by Product Type, 2024 and 2031
Figure 11. Gene Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Cell Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by End User, 2024 and 2031
Figure 14. Pharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 18. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Global Company Market Share Analysis, 2024
Figure 1. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Segmentation - Country
Figure 2. PEST Analysis
Figure 3. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Key Market Dynamics
Figure 4. Impact Analysis of Drivers and Restraints
Figure 5. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Revenue (US$ Million), 2024 - 2031
Figure 6. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by Service Type, 2024 and 2031
Figure 7. Drug Development and Manufacturing: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 8. Testing and Regulatory Services: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 9. Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 10. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by Product Type, 2024 and 2031
Figure 11. Gene Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 12. Cell Therapy: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 13. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Share (%) - by End User, 2024 and 2031
Figure 14. Pharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 15. Biopharmaceutical Companies: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 16. Others: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 17. Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market Breakdown by Key Countries, 2024 and 2031 (%)
Figure 18. China: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 19. Japan: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 20. India: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 21. Australia: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 22. South Korea: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 23. Rest of APAC: Asia Pacific Cell and Gene Therapy Contract Development and Manufacturing Organization Market - Revenue and Forecast, 2021 - 2031 (US$ Million)
Figure 24. Global Company Market Share Analysis, 2024
